Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$11.5M
Filings
144
Firms Hired
8
Active Period
2018–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Access to innovative kidney treatments. H.R.5074 - Protecting Young Minds Online Act, S.4510 - Kidney PATIENT Act of 2024. Pharmaceutical pricing proposals, Medicare pharmaceutical payment and access issues. Coverage of oral only End-Stage Renal Disease drugs.
Client expense: $650,000 · Firm income: —
Matched citations: H.R.5074
Access to innovative kidney treatments. H.R.5074 - Protecting Young Minds Online Act, S.4510 - Kidney PATIENT Act of 2024. Pharmaceutical pricing proposals, Medicare pharmaceutical payment and access issues. Coverage of oral only End-Stage Renal Disease drugs.
Client expense: $650,000 · Firm income: —
Matched citations: S.4510
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Client expense: $620,000 · Firm income: —
Matched citations: H.R.5074
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Client expense: $620,000 · Firm income: —
Matched citations: S.4510
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Client expense: $620,000 · Firm income: —
Matched citations: H.R.5074
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Client expense: $620,000 · Firm income: —
Matched citations: S.4510
Protecting Young Minds Online Act
2025 · second_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Client expense: — · Firm income: $90,000
Matched citations: H.R. 5074
Relief for Families of the Fallen Act
2025 · second_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Client expense: — · Firm income: $90,000
Matched citations: S.4510
H.R.5074, S.4510, Kidney Patient Act, Kidney Health Equity. Access to Innovative Kidney Treatments.
Client expense: $540,000 · Firm income: —
Matched citations: H.R.5074
H.R.5074, S.4510, Kidney Patient Act, Kidney Health Equity. Access to Innovative Kidney Treatments.
Client expense: $540,000 · Firm income: —
Matched citations: S.4510
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Client expense: $620,000 · Firm income: —
Matched citations: H.R.5074
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Client expense: $620,000 · Firm income: —
Matched citations: S.4510
Chronic Kidney Disease Improvement in Research and Treatment Act of 2023
2024 · fourth_quarter · Firm: CAPITOL CITY GROUP, LTD.
Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074-Kidney PATIENT Act of 2023; S 4510 Kidney PATIENT Act of 2024; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024. HR 6790 New "Era of Preventing End-Stage Kidney Disease Act; HR 5027-S4469 Kidney Disease Improvement in Research and Treatment Act of 2024.
Client expense: — · Firm income: $20,000
Matched citations: HR 5027
Kidney PATIENT Act of 2023
2024 · fourth_quarter · Firm: CAPITOL CITY GROUP, LTD.
Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074-Kidney PATIENT Act of 2023; S 4510 Kidney PATIENT Act of 2024; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024. HR 6790 New "Era of Preventing End-Stage Kidney Disease Act; HR 5027-S4469 Kidney Disease Improvement in Research and Treatment Act of 2024.
Client expense: — · Firm income: $20,000
Matched citations: HR 5074
New Era of Preventing End-Stage Kidney Disease Act
2024 · fourth_quarter · Firm: CAPITOL CITY GROUP, LTD.
Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074-Kidney PATIENT Act of 2023; S 4510 Kidney PATIENT Act of 2024; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024. HR 6790 New "Era of Preventing End-Stage Kidney Disease Act; HR 5027-S4469 Kidney Disease Improvement in Research and Treatment Act of 2024.
Client expense: — · Firm income: $20,000
Matched citations: HR 6790
Chronic Kidney Disease Improvement in Research and Treatment Act of 2024
2024 · fourth_quarter · Firm: CAPITOL CITY GROUP, LTD.
Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074-Kidney PATIENT Act of 2023; S 4510 Kidney PATIENT Act of 2024; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024. HR 6790 New "Era of Preventing End-Stage Kidney Disease Act; HR 5027-S4469 Kidney Disease Improvement in Research and Treatment Act of 2024.
Client expense: — · Firm income: $20,000
Matched citations: S4469
Kidney PATIENT Act of 2024
2024 · fourth_quarter · Firm: CAPITOL CITY GROUP, LTD.
Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074-Kidney PATIENT Act of 2023; S 4510 Kidney PATIENT Act of 2024; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024. HR 6790 New "Era of Preventing End-Stage Kidney Disease Act; HR 5027-S4469 Kidney Disease Improvement in Research and Treatment Act of 2024.
Client expense: — · Firm income: $20,000
Matched citations: S 4510
Kidney PATIENT Act of 2023
2024 · fourth_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5074
Kidney PATIENT Act of 2024
2024 · fourth_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Client expense: — · Firm income: $80,000
Matched citations: S.4510
Kidney PATIENT Act of 2023
2024 · fourth_quarter · Firm: THE HARPLE GROUP, LLC
HR 5074/S 4510, The Kidney Patient Act
Client expense: — · Firm income: $20,000
Matched citations: HR 5074
HR 5074/S 4510, The Kidney Patient Act
Client expense: — · Firm income: $20,000
Matched citations: S 4510
Issues related to Medicare ESRD benefit and chronic kidney disease management. H.R.5074/S.4510 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R.5074
Issues related to Medicare ESRD benefit and chronic kidney disease management. H.R.5074/S.4510 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.4510
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Client expense: $670,000 · Firm income: —
Matched citations: H.R.5074
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Client expense: $670,000 · Firm income: —
Matched citations: H.R.5074
Source: Senate LDA